Promus Premier is the Natick, Mass.-based medtech maker’s next-generation drug-eluting stent, made of a platinum-chromium alloy coated with the anti-restenosis drug everolimus.
“Japan is an important interventional cardiology market, and we believe the launch and success of this stent system in Japan will enhance Boston Scientific’s overall growth strategy in the DES market,” interventional cardiology president Kevin Ballinger said in prepared remarks.
Boston Scientific in December inked a co-promotion deal with The Medicines Co. for the Promus Premier stent.
The win is more good news for Boston Scientific, which recently beat a U.S. ban on its Guidezilla catheters, won FDA approval for a suite of next-generation defibrillators and heart failure devices and beat Wall Street estimates with its Q1 earnings.
BSX shares were down 0.2% today, trading at $12.59 as of about 1:35 p.m. EST. The stock has gained 4.7% since the start of the year.